Molecular Partners Presents Results from a Phase 2a Trial of Ensovibep in 12 COVID-19 Patients at ESWI 2021
News 06.12.2021 ZURICH-SCHLIEREN, Switzerland and CONCORD Mass., Dec. 06, 2021 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics, today announced the presentation of results from the Phase 2a study of ensovibep for COVID-19 patients as...